Avanir Pharmaceuticals Inc - Company & Market Research Reports

Avanir Pharmaceuticals focuses on the research, development and commercialization of novel medical and pharmaceutical treatments for people with central nervous system disorders. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. Avanir Pharmaceuticals was founded in 1988 and is headquartered in Aliso Viejo, California.


Schizophrenia - Pipeline Review, H1 2018 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H1 2018

  • Report
  • 334 Pages
From
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 - Product Thumbnail Image

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • Report
  • 433 Pages
From
Global Lifestyle Drugs Market 2017-2021 - Product Thumbnail Image

Global Lifestyle Drugs Market 2017-2021

  • Report
  • 91 Pages
From
Depression - Pipeline Review, H1 2018 - Product Thumbnail Image

Depression - Pipeline Review, H1 2018

  • Report
  • 490 Pages
From
Major Depressive Disorder - Pipeline Review, H2 2016 - Product Thumbnail Image

Major Depressive Disorder - Pipeline Review, H2 2016

  • Report
  • 201 Pages
From
Treatment Resistant Depression - Pipeline Review, H2 2016 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Review, H2 2016

  • Report
  • 74 Pages
From
Pharmapoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 - Product Thumbnail Image

Pharmapoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • Report
  • 392 Pages
From
Serotonin Transporter Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Serotonin Transporter Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Sigma Receptor Agonist -Pipeline Insight, 2018 - Product Thumbnail Image

Sigma Receptor Agonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Treatment Resistant Depression - Pipeline Insight, 2018 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Treatment Resistant Depression - Pipeline Review, H1 2016 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Review, H1 2016

  • Report
  • 64 Pages
From
Treatment Resistant Depression - Pipeline Review, H2 2015 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Review, H2 2015

  • Report
  • 62 Pages
From
Treatment Resistant Depression - Pipeline Review, H1 2015 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Review, H1 2015

  • Report
  • 61 Pages
From
Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027 - Product Thumbnail Image

Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027

  • Drug Pipelines
  • 169 Pages
From
Pain Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Pain Drug Development Pipeline Review, 2017

  • Report
  • 229 Pages
From
Onzetra Xsail 2016 U.S Promotional Report - Product Thumbnail Image

Onzetra Xsail 2016 U.S Promotional Report

  • Report
  • 21 Pages
From
Nuedexta 2016 U.S Promotional Report - Product Thumbnail Image

Nuedexta 2016 U.S Promotional Report

  • Report
  • 21 Pages
From
Global Neuropathy Pain Treatment Market 2017-2021 - Product Thumbnail Image

Global Neuropathy Pain Treatment Market 2017-2021

  • Report
  • 70 Pages
From
Global Central Nervous System Disorders Therapeutics Market 2016-2020 - Product Thumbnail Image

Global Central Nervous System Disorders Therapeutics Market 2016-2020

  • Report
  • 147 Pages
From
Dyskinesia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dyskinesia - Pipeline Review, H1 2018

  • Report
  • 160 Pages
From
Loading Indicator
adroll